Clinical trials: Locally Advanced Rectal Cancer (LARC)
Locally Advanced Rectal Cancer (LARC)
Application and Exploration of Personalized ctDNA-MRD Detection Technology in Predicting the Efficacy of Neoadjuvant Therapy for Rectal Cancer
This study is a single-center, prospective, observational clinical trial enrolling patients with locally advanced rectal cancer (cT3-4aN0M0 and cT1-4aN1-2M0).
- Trial name
- ctDNA-MRD-RC (NCT07393048)
- Testing
- Personalized ctDNA-MRD Detection
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing Friendship Hospital
Locally Advanced Rectal Cancer
Fruquintinib Plus PD-1 Antibody in pMMR / MSS Locally Advanced Rectal Cancer (LARC) With High Immune Score
This is a prospective, one arm phase II study aimed to observe the efficacy and safety of tislelizumab combined with fruquintinib in treatment of patients with pMMR / MSS locally advanced rectal cancer with high immune score.
- Trial name
- NCT04989855
- Testing
- Fruquintinib plus Tislelizumab
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Sun Yat-sen University
Locally Advanced Rectal Cancer (LARC), Immunotherapy
Personalized Long-course Radiotherapy Plus Chemotherapy With or Without Immunotherapy for LARC: PALACE Study
The study is a multicenter, randomized controlled, phase III clinical study, and the purpose of the study is to explore the complete response rate (CR, Defined as pathological complete response (pCR) + Clinical complete response…
- Conditions
- Locally Advanced Rectal Cancer (LARC), Immunotherapy, Radiotherapy, Total Neoadjuvant Therapy
- Trial name
- NCT07020247
- Testing
- Anti-PD-1 antibody drug named Serplulimab, Radiotherapy, Chemotherapy
- Where
- China
- Volunteers
- 184 people
- Sponsor
- West China Hospital
Locally Advanced Rectal Cancer
A Trial of Neoadjuvant mFOLFOXIRI Versus CRT in the EMVI Positive LARC
Extramural Vascular Invasion Positive(EMVI+) is a high risk of distant metastasis for locally advanced rectal cancer(LARC) after resection.
- Trial name
- NCT04423965
- Testing
- mFOLFOXIRI, Chemoradiotherapy
- Where
- China
- Volunteers
- 220 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Locally Advanced Rectal Cancer (LARC)
Optimizing Patient Selection for Surgery Using Pathologic Analysis Following Neoadjuvant Therapy in Locally Advanced Rectal Cancer
This interventional, non-randomized, prospective trial aims to evaluate the role of endoscopic resection following neoadjuvant treatment in patients with locally advanced rectal cancer.
- Trial name
- OPAL (NCT06761287)
- Testing
- Endoscopic resection, Short interval restaging, Total mesorectal excision
- Where
- Belgium
- Volunteers
- 20 people
- Sponsor
- Centre Hospitalier Universitaire Saint Pierre
Locally Advanced Rectal Cancer (LARC)
Application of PET/MRI in the Evaluation of the Efficacy of Neoadjuvant Therapy for Locally Advanced Rectal Cancer
This study plans to include LARC patients receiving neoadjuvant therapy at this center, conducting PET/CT and PET/MR examinations before treatment, and PET/MR examinations before surgery after neoadjuvant therapy.
- Trial name
- NCT06653452
- Testing
- 18F-FDG PET/CT and PET/MR scan, 68Ga-FAPI-04 PET/CT and PET/MR scan
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking Union Medical College Hospital
Locally Advanced Rectal Cancer
Evaluation of Inflammatory Markers in LARC Patients
Introduction: In locally advanced rectal cancers (LARC), TNM staging is far from optimal. We aimed to investigate the value of previously described circulating biomarkers as predictors of prognosis.
- Trial name
- NCT05893667
- Testing
- Inflammatory markers
- Volunteers
- 245 people
- Sponsor
- Hospital Pedro Hispano
Rectal Cancer
Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy, HLX07and Serplulimab in LARC
The study is a multicenter, open-label, phase II clinical study, and the purpose of the study is to explore the complete response rate (CR, Defined as pathological complete response (pCR) + Clinical complete response (cCR)) of…
- Trial name
- NCT06542588
- Testing
- HLX07(anti EGFR antibody) and Serplulimab(anti PD-1 antibody)
- Where
- 3 sites in China
- Volunteers
- 29 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Locally Advanced Rectal Cancer (LARC)
PCSK9 Inhibitor and PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy for pMMR/MSS Locally Advanced Rectal Cancer
This is a single-center, open-label, single-arm clinical study aimed at conducting a preliminary evaluation of the efficacy and safety of combining PCSK9 inhibitors and PD-1 inhibitors (dual inhibitors) with neoadjuvant…
- Trial name
- NCT06933251
- Testing
- Neoadjuvant Chemoradiotherapy Combined with PD-1 inhibitor Immunotherapy and PCSK9 Inhibitor Therapy
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Guangdong Provincial People's Hospital
Rectal Neoplasms
Rectal Artery Infusion Chemotherapy Combined With Anti-PD1 Antibody for MSS LARC
The purpose of this study is to explore whether rectal artery infusion chemotherapy combined with anti-PD1 antibody is an effective neoadjuvant therapy for the microsatellite stable locally advanced rectal cancer.
- Trial name
- RAIC (NCT05307198)
- Testing
- Oxaliplatin, Rectectomy, Capecitabine
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Hyperthermia, Radiotherapy
Hyperthermia Combined With Neoadjuvant Radiochemotherapy for LARC
The purpose of this study is to determine whether adding deep hyperthermia to neoadjuvant concurrent radiochemotherapy could improve T-downstaging rate for locally advanced rectal cancer (LARC).
- Trial name
- PUTHRC-001 (NCT05070832)
- Testing
- Deep Hyperthermia
- Volunteers
- 142 people
- Sponsor
- Peking University Third Hospital
Locally Advanced Rectal Cancer
A Clinical Study Conducted in Multiple Centers Evaluating Escalating Doses of Veliparib in Combination With Capecitabine and Radiation in Patients With Locally Advanced Rectal Cancer
An open-label, Phase 1b, dose escalation study evaluating the safety and tolerability of the PARP inhibitor Veliparib in combination with capecitabine and radiation in subjects with locally advanced rectal cancer (LARC).
- Trial name
- NCT01589419
- Testing
- veliparib, capecitabine, radiation
- Where
- 6 sites in United States, Australia
- Volunteers
- 32 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Locally Advanced Rectal Cancer (LARC)
Neoadjuvant Chemoradiotherapy Plus PD-1 Blockade ± CTLA-4 Blockade for Low/Intermediate-Risk Locally Advanced Rectal Cancer (pMMR/MSS): A National Multicenter, Prospective, Randomized Controlled Trial
The goal of this clinical trial is to learn whether adding ipilimumab N01 to standard pre-surgery treatment with radiation, chemotherapy, and sintilimab can improve outcomes for people with low- or intermediate-risk, locally…
- Trial name
- NCT07879599
- Testing
- Ipilimumab & Sintilimab, Sintilimab
- Volunteers
- 120 people
- Sponsor
- Yao Hongwei
Rectal Cancer
The Efficacy of Primary Total Mesorectal Excision (TME) Surgery Versus Neoadjuvant Chemotherapy Combined With TME Surgery in Low-risk Locally Advanced Rectal Cancer
Comparative analysis of the clinical efficacy between primary Total Mesorectal Excision (TME) surgery and neoadjuvant chemotherapy combined with TME surgery for low-risk locally advanced rectal cancer.
- Trial name
- TaLaR-02 (NCT05984485)
- Testing
- neoadjuvant chemotherapy plus total mesorectal excision, total mesorectal excision
- Where
- 6 sites in China
- Volunteers
- 766 people
- Sponsor
- Sun Yat-sen University
Rectal Cancer
Short-course Radiation (SCRT) Followed by 6 Cycles of Cadonilimab Plus MFOLFOX6 As Neoadjuvant Therapy for Patients with Locally Advanced Rectal Cancer (LARC): a Multicenter, Two-arm Parallel, Open-label, Randomised Phase III Trial (NeoCaCRT-III)
The goal of this clinical trial is to learn if neoadjuvant short-course radiation (SCRT) followed by 6 cycles of cadonilimab plus mFOLFOX6 works to treat patients with locally advanced rectal cancer (LARC).
- Trial name
- NeoCaCRT-III (NCT06832917)
- Testing
- AK104 plus, Chemo only
- Volunteers
- 238 people
- Sponsor
- Wan He
Efficacy and Safety of Short-course Radiotherapy in Total Neoadjuvant Therapy Combined With Enlonstobart for pMMR Locally Advanced Rectal Cancer
Short-course Radiotherapy in TNT Combined With Enlonstobart for pMMR LARC
Efficacy and safety of short-course radiotherapy in total neoadjuvant therapy combined with enlonstobart for pMMR locally advanced rectal cancer
- Trial name
- NCT07448077
- Testing
- Experimental: short-course radiotherapy and immunotherapy, Chemoradiotherapy
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Hebei Medical University Fourth Hospital
Locally Advanced Rectal Cancer (LARC)
Development and Validation of a Post-operative Risk Of Local Recurrence Model Integrating Serology and Evalution (PROMISE) in Local Advanced Rectal Cancer Receiving Neoadjuvant Therapy: a Multicenter Study
Local recurrence (LR) in locally advanced rectal cancer (LARC) correlated with poor survival and impaired quality of life. The aim of this study was to develop and validate machine learning (ML) models integrating…
- Trial name
- PROMISE model (NCT07351708)
- Volunteers
- 2,315 people
- Sponsor
- Cai Zerong
Locally Advanced Rectal Cancer (LARC)
Total Neoadjuvant Treatment With or Without Tislelizumab for Locally Advanced Rectal Cancer.
This prospective, multi-center, phase II randomized controlled trial will evaluate the actual benefit of adding immunotherapy with tislelizumab to the currently most effective approach against LARC, namely TNT.
- Trial name
- TOTAL (NCT06940388)
- Testing
- Tislelizumab, Total neoadjuvant therapy (TNT)
- Where
- 2 sites in Germany, Israel
- Volunteers
- 134 people
- Sponsor
- brenner baruch
Rectal Cancer, Rectal Adenocarcinoma
SCRT Followed by CAPOX + Bev ± PD-1 Inhibitor for TNT in LARC
This study aims to evaluate the efficacy and safety of short-course radiotherapy combined with CAPOX plus bevacizumab with or without a PD-1 inhibitor in patients with locally advanced rectal cancer (LARC).
- Conditions
- Rectal Cancer, Rectal Adenocarcinoma, Rectal Cancer, Radiotherapy, Rectal Cancer Patients
- Trial name
- NCT07198165
- Testing
- PD-1 inhibitor based immunotherapy
- Where
- China
- Volunteers
- 104 people
- Sponsor
- Ruijin Hospital
Rectal Cancer, Neoadjuvant Therapies
Modified Long-Course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for MSS/pMMR High-risk Mid/Low LARC (MODIFI-RC-I)
The goal of this clinical trial is to evaluate whether a total neoadjuvant therapy (TNT) regimen combining long-course chemoradiotherapy, sequential chemotherapy, and PD-1 inhibitor can improve response rates, enhance…
- Conditions
- Rectal Cancer, Neoadjuvant Therapies, Immune Checkpoint Therapy, Radiotherapy
- Trial name
- NCT06923345
- Testing
- Reduced CTV, Conventional CTV
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University